Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has reported Total Non-Current Liabilities for 13 years, with the latest figure at $46.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 19.87% year-over-year to $46.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.3 million (down 19.87% YoY) and the FY2025 annual result came in at $52.2 million, down 17.62% from the prior year.
• Total Non-Current Liabilities slipped to $46.3 million in Q1 2026 per RCKT's latest filing, from $52.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $70.8 million in Q4 2023 and troughed at $42.5 million in Q1 2022.
• A 5-year average of $56.0 million and a median of $56.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 41.0% in 2022, down 55.93% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $59.5 million in 2022, then gained by 18.99% to $70.8 million in 2023, then slipped by 10.6% to $63.3 million in 2024, then slipped by 17.62% to $52.2 million in 2025, then fell by 11.24% to $46.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $46.3 million, $52.2 million, and $53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.